LICENSED cultivator and manufacturer of medical-grade cannabis extracts and products, MG Health is tripling its output capacity after a successful international funding round, raising $18 million in capital.

The funding was secured after the company began distributing into key developed markets in 2021.  

MG Health will expand its portfolio of medicinal cannabis strains and formulated extracts to meet the wider demand in key export markets including Germany, Australia, Poland and Israel.

Based high in the mountains of Lesotho, MG Health is one of a handful companies worldwide that have been confirmed as compliant with European Union (EU) good manufacturing practice (GMP) for medical cannabis, allowing it to export its medicinal cannabis flower and extracts as an Active Pharmaceutical Ingredient (API) to pharmacies in the EU and select other markets.

“What makes our pharmaceutical grade product so unique and in demand is how pure it is. It is produced in the pristine environment of Lesotho, 2 000 metres above sea level, where the exceptionally clean air quality and our state-of-the-art facilities enable us to consistently produce a non-irradiated product that is on par with the highest quality in the world,” says MG Health’s Chief Executive Officer, Andre Bothma.

Since starting with research and development in 2018, MG Health has looked to incorporate the many lessons learnt over the last five years to optimise its production for the global medical cannabis market and further support its in country distribution partners.